Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9953925 | Reports of Practical Oncology & Radiotherapy | 2018 | 7 Pages |
Abstract
Conclusions: When given concurrently with radiotherapy, Cetuximab and triweekly Cisplatin demonstrated comparable efficacy for AJCC 8th Edition stage I-II p16-positive OPSCC. However, Cetuximab appeared to be associated with higher rates of treatment failure and cancer-related deaths in stage III disease. Upon availability of the RTOG 1016 trial results, analysis based on the revised HPV-based staging should be performed to confirm these findings.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Nuclear and High Energy Physics
Authors
Onita Bhattasali, Lester D.R. Thompson, Iman A. Abdalla, Jergin Chen, Shawn Iganej,